We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Sustained-Release Contact Lens Could Help Treat Glaucoma

By HospiMedica International staff writers
Posted on 06 Aug 2009
Innovative prototype contact lenses effectively dispense medication to the eye, at an adjustable and constant rate of flow. More...


Researchers at Children's Hospital Boston (CHB; MA, USA), the Massachusetts Eye and Ear Infirmary (Boston, MA, USA), and the Massachusetts Institute of Technology (MIT; Boston, USA) created a two-layer contact lens that is comprised of an inner drug-bearing biodegradable polymer film made of polylactic-co-glycolic acid (PLGA), and an outer coating made out of Poly(2-hydroxyethyl methacrylate) (pHEMA), a polymer that forms a hydrogel in water. In laboratory testing, the prototype lenses dispensed ciprofloxacin--an antibiotic often used in eye drops--for 30 days; in other tests, the lenses continued releasing the drug for up to 100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay. Possible applications include treatment of conditions such as glaucoma and dry-eye, which require frequent daily eye drops. The study describing the new lens was published in the July 2009 issue of Investigative Ophthalmology and Visual Science.

"Patients taking eye drops multiple times daily may absorb as little as 1 to 7 percent of the intended dose into the eye due to blinking and tearing. This prototype of a contact lens allows the delivery of large or at least therapeutically relevant quantities of drug for extended periods of time, meaning at least a month, with what's called zero-order kinetics,” said lead author Daniel Kohane, M.D, Ph.D., director of the laboratory for biomaterials and drug delivery at CHB. "There may be applications in the third world, in places where storage of medication or availability of medications or physicians is restricted.”

While other drug-releasing contact lenses have been developed, none so far have been able to achieve a constant, steady release of substantial amounts of drug; typically, a burst of drug is delivered in the first few hours, followed by rapidly dwindling amounts that are too low to be therapeutic. This may cause toxicity, as well as hamper the drug's effectiveness.

Related Links:
Children's Hospital Boston
Massachusetts Eye and Ear Infirmary
Massachusetts Institute of Technology



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.